With the clock ticking on a Nov. 20 PDUFA date, Swedish Orphan Biovitrum AB (Sobi) swooped in to acquire global rights to emapalumab (NI-0501) from developer Novimmune SA in exchange for CHF50 million (US$50.3 million) up front in cash and additional payments totaling CHF400 million (US$402.3 million) over an eight-year period.